N. Esiashvili, M. Goodman, R. Marcus, and . Jr, Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades, Journal of Pediatric Hematology/Oncology, vol.30, issue.6, pp.425-430, 2008.
DOI : 10.1097/MPH.0b013e31816e22f3

C. Turc-carel, I. Philip, M. Berger, T. Philip, and G. Lenoir, [Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma], C R Seances Acad Sci III, issue.23, pp.2961101-1103, 1983.

S. Donaldson, T. M. Link, M. Glicksman, A. Gilula, L. et al., A multidisciplinary study investigating radiotherapy in Ewing???s sarcoma: end results of POG #8346, International Journal of Radiation Oncology*Biology*Physics, vol.42, issue.1, pp.125-135, 1998.
DOI : 10.1016/S0360-3016(98)00191-6

S. Cotterill, S. Ahrens, M. Paulussen, H. Jurgens, P. Voute et al., Prognostic Factors in Ewing???s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing???s Sarcoma Study Group, Journal of Clinical Oncology, vol.18, issue.17, pp.183108-3114, 2000.
DOI : 10.1200/JCO.2000.18.17.3108

A. Craft, S. Cotterill, J. Bullimore, and D. Pearson, Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1) United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party, Eur J Cancer, issue.7, pp.331061-1069, 1997.

R. Jenkin, I. Al-fawaz, M. Shabanah, A. Allam, M. Ayas et al., Metastatic Ewing sarcoma/PNET of bone at diagnosis: Prognostic factors?a report from Saudi Arabia, Medical and Pediatric Oncology, vol.21, issue.4, pp.383-389, 2001.
DOI : 10.1002/mpo.1214

P. Meyers, M. Krailo, M. Ladanyi, K. Chan, S. Sailer et al., High-Dose Melphalan, Etoposide, Total-Body Irradiation, and Autologous Stem-Cell Reconstitution as Consolidation Therapy for High-Risk Ewing???s Sarcoma Does Not Improve Prognosis, Journal of Clinical Oncology, vol.19, issue.11, pp.2812-2820, 2001.
DOI : 10.1200/JCO.2001.19.11.2812

M. Paulussen, S. Ahrens, S. Burdach, A. Craft, B. Dockhorn-dworniczak et al., Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies, European Intergroup Cooperative Ewing Sarcoma Studies

B. Kushner, P. Meyers, W. Gerald, J. Healey, L. Quaglia et al., Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults., Journal of Clinical Oncology, vol.13, issue.11, pp.132796-2804, 1995.
DOI : 10.1200/JCO.1995.13.11.2796

D. Dahlin, M. Coventry, and P. Scanlon, Ewing??s Sarcoma, The Journal of Bone & Joint Surgery, vol.43, issue.2, pp.185-192, 1961.
DOI : 10.2106/00004623-196143020-00004

G. Schleiermacher, M. Peter, O. Oberlin, T. Philip, R. H. Mechinaud et al., Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor, Journal of Clinical Oncology, vol.21, issue.1, pp.85-91, 2003.
DOI : 10.1200/JCO.2003.03.006

P. Masarachia, M. Weinreb, R. Balena, and G. Rodan, Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones, Bone, vol.19, issue.3, pp.281-290, 1996.
DOI : 10.1016/8756-3282(96)00182-2

M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons et al., Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure., Journal of Clinical Investigation, vol.88, issue.6, pp.2095-2105, 1991.
DOI : 10.1172/JCI115539

D. Heymann, B. Ory, F. Blanchard, M. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020

R. Coleman, Risks and benefits of bisphosphonates, British Journal of Cancer, vol.2, issue.11, pp.1736-1740, 2008.
DOI : 10.1093/jnci/djm025

B. Ory, M. Heymann, A. Kamijo, F. Gouin, D. Heymann et al., Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice, Cancer, vol.91, issue.11, pp.2522-2529, 2005.
DOI : 10.1002/cncr.21530

D. Heymann, B. Ory, F. Gouin, J. Green, and F. Redini, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004.
DOI : 10.1016/j.molmed.2004.05.007

G. Odri, S. Dumoucel, G. Picarda, S. Battaglia, F. Lamoureux et al., Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients, Cancer Research, vol.70, issue.19, pp.707610-7619, 2010.
DOI : 10.1158/0008-5472.CAN-09-4272

A. Marten, M. Lilienfeld-toal, M. Buchler, and J. Schmidt, Zoledronic Acid has Direct Antiproliferative and Antimetastatic Effect on Pancreatic Carcinoma Cells and Acts as an Antigen for ??2 ??/?? T Cells, Journal of Immunotherapy, vol.30, issue.4, pp.370-377, 2007.
DOI : 10.1097/CJI.0b013e31802bff16

B. Kubista, K. Trieb, F. Sevelda, C. Toma, F. Arrich et al., Anticancer effects of zoledronic acid against human osteosarcoma cells, Journal of Orthopaedic Research, vol.2, issue.6, pp.241145-1152, 2006.
DOI : 10.1002/jor.20129

S. Boissier, M. Ferreras, O. Peyruchaud, S. Magnetto, F. Ebetino et al., Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases, Cancer Res, issue.11, pp.602949-2954, 2000.

C. Walter, A. Pabst, T. Ziebart, M. Klein, and B. Al-nawas, Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro, Oral Diseases, vol.65, issue.Suppl, pp.194-199, 2011.
DOI : 10.1111/j.1601-0825.2010.01720.x

URL : https://hal.archives-ouvertes.fr/hal-00599899

L. Wu, L. Zhu, W. Shi, J. Zhang, D. Ma et al., Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells, European Journal of Pharmacology, vol.602, issue.1
DOI : 10.1016/j.ejphar.2008.10.043

K. Scotlandi, S. Benini, M. Manara, M. Serra, P. Nanni et al., Murine model for skeletal metastases of Ewing's sarcoma, Journal of Orthopaedic Research, vol.14, issue.6, pp.959-966, 2000.
DOI : 10.1002/jor.1100180616

T. Wolfe, S. Pillai, B. Hildreth, L. Lanigan, C. Martin et al., Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice, Clinical & Experimental Metastasis, vol.173, issue.Suppl 1, pp.377-389, 2011.
DOI : 10.1007/s10585-011-9377-9

L. Endo-munoz, A. Cumming, D. Rickwood, D. Wilson, C. Cueva et al., Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases, Cancer Research, vol.70, issue.18, pp.707063-7072, 2010.
DOI : 10.1158/0008-5472.CAN-09-4291

T. Hiraga, P. Williams, A. Ueda, D. Tamura, and T. Yoneda, Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model, Clinical Cancer Research, vol.10, issue.13, pp.4559-4567, 2004.
DOI : 10.1158/1078-0432.CCR-03-0325

A. Chaturvedi, L. Hoffman, A. Welm, S. Lessnick, and M. Beckerle, The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma, Genes & Cancer, vol.3, issue.2, pp.102-116
DOI : 10.1177/1947601912457024

S. Strauss, T. Ng, A. Mendoza-naranjo, J. Whelan, and P. Sorensen, Understanding Micrometastatic Disease and Anoikis Resistance in Ewing Family of Tumors and Osteosarcoma, The Oncologist, vol.15, issue.6, pp.627-635, 2010.
DOI : 10.1634/theoncologist.2010-0093

. Odri, Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing???s sarcoma via inhibition of cell migration, BMC Cancer, vol.15, issue.6, p.169, 2014.
DOI : 10.1634/theoncologist.2010-0093